Luk Vandenberghe, Ph.D.

Scientific Co-Founder and Adviser, and Board Member

Luk is the Grousbeck Family Chair in Gene Therapy and director of the Grousbeck Gene Therapy Center at Massachusetts Eye and Ear, and associate professor of ophthalmology at Harvard Medical School. He is a renowned scientific leader in AAV gene therapy research and development and a scientific co-founder and adviser to Affinia Therapeutics. He has authored over 80 publications, holds more than 12 patents, and is a co-inventor of AAV9, a vector used in many gene therapies. Luk is also co-founder of the gene therapy companies Akouos, Odylia, and Albamunity. He received an engineering degree and a Ph.D. in molecular medicine at the University of Leuven, Belgium, after which he did his postgraduate training at the University of Pennsylvania in translational cell and gene therapy.